Want to see BCAX full AI Analyst Report?
Total Valuation
Bicara Therapeutics Inc. has a market cap or net worth of $1.61B. The enterprise value is $1.52K.
Market Cap$1.61B
Enterprise Value$1.52K
Share Statistics
Bicara Therapeutics Inc. has 66,172,935 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,172,935
Owned by Insiders21.71%
Owned by Institutions19.34%
Financial Efficiency
Bicara Therapeutics Inc.’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -38.60%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-38.60%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-1.34M
Employee Count103
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bicara Therapeutics Inc. is ―. Bicara Therapeutics Inc.’s PEG ratio is -0.07.
PE Ratio―
PS Ratio0.00
PB Ratio2.29
Price to Fair Value2.29
Price to FCF-8.59
Price to Operating Cash Flow-12.23
PEG Ratio-0.07
Income Statement
In the last 12 months, Bicara Therapeutics Inc. had revenue of 0.00 and earned -137.95M in profits. Earnings per share was -2.52.
Revenue0.00
Gross Profit0.00
Operating Income-155.60M
Pretax Income-137.73M
Net Income-137.95M
EBITDA-137.63M
Earnings Per Share (EPS)-2.52
Cash Flow
In the last 12 months, operating cash flow was -134.85M and capital expenditures -400.00K, giving a free cash flow of -135.25M billion.
Operating Cash Flow-134.85M
Free Cash Flow-135.25M
Free Cash Flow per Share-2.04
Dividends & Yields
Bicara Therapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.44
52-Week Price Change111.68%
50-Day Moving Average25.91
200-Day Moving Average20.34
Relative Strength Index (RSI)41.83
Average Volume (3m)829.98K
Important Dates
Bicara Therapeutics Inc. upcoming earnings date is Nov 17, 2026, Before Open (Confirmed).
Last Earnings DateAug 11, 2026
Next Earnings DateNov 17, 2026
Ex-Dividend Date―
Financial Position
Bicara Therapeutics Inc. as a current ratio of 14.58, with Debt / Equity ratio of 0.25%
Current Ratio14.58
Quick Ratio14.58
Debt to Market Cap0.00
Net Debt to EBITDA0.69
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bicara Therapeutics Inc. has paid 217.00K in taxes.
Income Tax217.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Bicara Therapeutics Inc. EV to EBITDA ratio is -6.00, with an EV/FCF ratio of -7.70.
EV to Sales0.00
EV to EBITDA-6.00
EV to Free Cash Flow-7.70
EV to Operating Cash Flow-7.72
Balance Sheet
Bicara Therapeutics Inc. has $497.26M in cash and marketable securities with $1.16M in debt, giving a net cash position of $496.10M billion.
Cash & Marketable Securities$497.26M
Total Debt$1.16M
Net Cash$496.10M
Net Cash Per Share$7.50
Tangible Book Value Per Share$7.34
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bicara Therapeutics Inc. is $33.18, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$33.18
Price Target Upside22.80% Upside
Analyst ConsensusModerate Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast-63.70%